NCT00729599

CompletedPhase 3

Safety Dermatological Evaluation: Acceptability With Odontol...

Sanofi Source

Compare

Other study identifiers

Sponsor study identifier

CPYRY_L_04020

Study Type

interventional

Actual enrollment (reported)

31

Locations

1 country

Sites

1

Timeline

Study Start

July 2008

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

August 2008

Actual (reported)

Study Completion

Not reported

Date not reported

Brief Summary

To prove the safety, in normal conditions, of the Cepacol Teen, a formulation to odontological usage.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 31 participants
Study completion date: Not reported
Date not reported
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
July 2008
Date type not reported
This date has not been verified as actual or estimated.
Primary Completion
August 2008
Actual (reported)
First Submitted
August 4, 2008
Actual (reported)
First Posted
August 7, 2008
Actual (reported)

Last Updated: March 4, 2009
Status Verified: March 2009
Last Update Submitted: March 3, 2009

Conditions

Hygiene

Outcome Measures

Primary Outcomes (1)

Patients will be evaluated according to the adverse reactions and the intensity of them.
21 days

Study Arms (1)

1

EXPERIMENTAL

Cetylpyridinium chloride during 21 consecutive days.

Drug: Cetylpyridinium chloride

Interventions

Cetylpyridinium chlorideDrug

Cetylpyridinium chloride during 21 consecutive days.

1

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age10 Years - 60 Years

Sexall

Healthy VolunteersYes

Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

Integral buccal mucous (without oral pathologies);
Normal odontological exams;

You may not qualify if:

Sponsors & Collaborators

Sanofi
Industrylead

Study Sites (1)

Sanofi-aventis

São Paulo, São Paulo, Brazil

MeSH Terms

Interventions

Cetylpyridinium

Intervention Hierarchy (Ancestors)

Pyridinium CompoundsPyridinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

Jaderson Lima, MD
Sanofi-aventis administrative office Brazil
STUDY DIRECTOR

Enrollment

31 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 3
Allocation: NA
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: INDUSTRY

Study Record Dates

First Submitted

August 4, 2008

First Posted

August 7, 2008

Study Start

July 2008

Date type not reported

This date has not been verified as actual or estimated.

NCT00785148

Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid) - Safety

Phase 3Completed

NCT00785642

Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid) - Safety.

Phase 3Completed

NCT00664391

Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Breeze

Phase 3Completed

NCT00785850

Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower - Safety.

Phase 3Completed

NCT00663390

Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Delicata Pocket BR

Phase 3Completed

NCT00933413

Dermacyd Silver Frutal (Lactic Acid) - Acceptability.

Phase 3Completed

Lactation or gestational risk or gestation;
Use of Antiinflammatory or immunosuppression drugs 15 days before the study;
Being in odontological treatment;
Pathological or mucous disease which can interfere or active gynaecological disease which may interfere wtih study results;
Personal history of allergic disease in the area to be treated;
Allergic or atopic history;

Contact the study team to confirm eligibility.

Primary Completion

August 2008

Actual (reported)

Last Updated

March 4, 2009

Record last verified: 2009-03

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00729599
Data provider: ClinicalTrials.gov
Source updated: 2009-03-04
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:28:08 UTC

Locations

BR(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

1

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations